What is Mironid?
Mironid is a dynamic biotechnology company dedicated to the discovery and development of novel small-molecule therapeutics. The firm specializes in targeting cAMP-degrading phosphodiesterase enzymes, a mechanism with significant potential for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare renal conditions. By leveraging a patient-centric research model, Mironid aims to transform the treatment landscape for individuals suffering from chronic kidney diseases. The company's scientific rigor and focus on precision medicine have established it as a formidable entity within the global biopharma ecosystem, bridging the gap between academic innovation and commercial-scale drug development.
How much funding has Mironid raised?
Mironid has raised a total of $52.2M across 2 funding rounds:
Angel/Seed
$6.2M
Series B
$46M
Angel/Seed (2016): $6.2M with participation from The Scottish Investment Bank, Epidarex Capital, and University of Strathclyde Glasgow
Series B (2026): $46M led by BGV (BioGeneration Ventures), Epidarex Capital, Roche, Sofinnova Partners, University of Strathclyde Glasgow, and Scottish National Investment Bank
Key Investors in Mironid
BGV (BioGeneration Ventures)
A venture capital firm specializing in seed and early-stage investments for innovative life science companies, with a strong focus on European biotech innovation.
Epidarex Capital
A transatlantic venture capital firm that partners with founders to build breakthrough life science companies in emerging hubs, leveraging deep scientific networks.
Roche
A global pioneer in pharmaceuticals and diagnostics, Roche is a leader in personalized healthcare, focusing on targeted therapies and innovative diagnostic solutions.
What's next for Mironid?
With the successful closure of this major strategic investment, Mironid is well-positioned to advance its lead candidates through critical clinical development phases. The influx of capital will likely be deployed to expand research capabilities, strengthen the internal pipeline, and potentially initiate new partnerships to broaden the reach of its therapeutic platform. As the company transitions into a more mature stage of its lifecycle, the focus will shift toward regulatory milestones and the validation of its drug development programs in human clinical trials. The continued support from its diverse investor base provides both the financial stability and the strategic expertise required to navigate the complex regulatory and commercial challenges inherent in the biotechnology industry.
See full Mironid company page
